{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-243082","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.338165+00:00","generated_at":"2026-06-10T08:05:08.889123+00:00","sec_items":["7.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Vaccinex to present ActivMAb platform and pepinemab PDAC study at two conferences","bullets":["Presentation at CHI's DOT Conference on Sept 28: new ActivMAb application for multi-pass membrane proteins including CXCR5.","Poster on Phase 1b/2a pepinemab + avelumab in chemotherapy-refractory metastatic PDAC at AACR Pancreatic Cancer conference on Sept 29.","Dr. Ernest Smith to present at DOT; Dr. Luis Ruffolo of University of Rochester presents the PDAC poster.","Poster will be available on Vaccinex website under 'Investors/Presentations' starting Sept 27 at 5:30 pm ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-243082","json":"https://secwatch.observer/filing/0001193125-23-243082.json","markdown":"https://secwatch.observer/filing/0001193125-23-243082.md","text":"https://secwatch.observer/filing/0001193125-23-243082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523243082/0001193125-23-243082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523243082/d483793d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:05:08.889123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}